Skip to content
Clinical Trials – home

Diagnostic-consultative center “Aleksandrovska” EOOD

Verified siteinfo

Bulgaria Georgy Sofiiski Str 1, 1431 Sofia, Bulgaria

  • 74 trials recruiting
  • Asthma · Dermatitis atopic · Chronic spontaneous urticaria
  • Adults and children

About Specializations

Diagnostic-consultative center “Aleksandrovska” EOOD in Sofia, Bulgaria specialises in clinical trials of conditions such as Asthma, Dermatitis atopic, Chronic spontaneous urticaria, Obesity, and other specialisations. This site conducts important research.

Main research areas of the site

Digestive System Diseases

Clinical research at Diagnostic-consultative center “Aleksandrovska” EOOD includes studies in Digestive System Diseases, with a strong focus on Crohn's disease. These trials are designed to evaluate new treatment options and better understand how therapies may improve disease control and intestinal health.

  • Testing new therapies for Crohn's disease
  • Assessing treatment effectiveness in Digestive System Diseases
  • Studying responses to therapy in patients with inflammatory bowel conditions

The site is contributing to research that aims to improve care for people living with chronic digestive inflammation and to support more effective long-term management strategies.

Immune System Diseases

Another key area of work is Immune System Diseases, especially chronic spontaneous urticaria. The trials here are focused on evaluating whether new treatments can reduce symptoms such as hives and itch while also examining safety and overall tolerability.

  • Investigating therapies for chronic spontaneous urticaria
  • Measuring symptom improvement in immune-related skin conditions
  • Checking safety and tolerability of emerging treatment options

These studies help advance care for patients whose immune-related symptoms can be persistent and difficult to manage.

Skin and Connective Tissue Diseases

Research in Skin and Connective Tissue Diseases at the Sofia site overlaps with immune-mediated skin disorders, particularly chronic spontaneous urticaria. The clinical trials are aimed at improving diagnostic understanding and testing whether new therapies can provide better relief from visible and uncomfortable skin symptoms.

  • Evaluating treatments for hives without a known cause
  • Exploring symptom relief in skin-related immune disorders
  • Supporting better management of chronic skin conditions

With multiple investigators involved, the center is helping expand research options for patients affected by ongoing skin and connective tissue disease symptoms.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Site location
Georgy Sofiiski Str 11431 SofiaBulgaria
Recruiting now
74 trials
Conditions studied
99
Partner status
Verified site

More sites in SofiaBulgaria

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

202 clinical trials

Cardiac failure

Recruiting

Study of maridebart cafraglutide for patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Obesity+2

Recruiting

Effect of zenagamtide on major adverse cardiovascular events in overweight or obese adults with established atherosclerotic cardiovascular disease

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years
  • Substances:Zenagamtide
  • Sponsor:Novo Nordisk A/S

Graves' disease

Recruiting

Phase 3 Randomized Placebo‑Controlled Study of Efgartigimod Alfa in Adults with Graves’ Disease Inadequately Controlled by Antithyroid Drugs

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

A Phase 3 Study of Efimosfermin Alfa to Assess Safety and Tolerability in Adults with F2‑F3 Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Efimosfermin alfa
  • Sponsor:Glaxosmithkline Research & Development Limited

BI 3000202 in Patients with Moderate to Severe Systemic Lupus Erythematosus

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:BI 3000202
  • Sponsor:Boehringer Ingelheim Espana S.A.

Eczema nummular

Recruiting

A study to evaluate the effectiveness and safety of lebrikizumab in adults with nummular eczema who do not respond well to topical corticosteroids.

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Lebrikizumab
  • Sponsor:Almirall S.A.

A Phase III Study of Survodutide in Adults with Compensated NASH Cirrhosis to Assess Liver Outcomes and Safety

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Survodutide
  • Sponsor:Boehringer Ingelheim International GmbH

A Phase III trial of BI 456906 weekly injections in adults with NASH and stage 2‑3 liver fibrosis

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Survodutide
  • Sponsor:Boehringer Ingelheim International GmbH

A study to evaluate the long-term safety and effectiveness of barzolvolimab in patients with chronic spontaneous urticaria

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Epinephrine
  • Sponsor:Celldex Therapeutics Inc.

A study to evaluate the effectiveness and safety of remibrutinib in patients with secondary progressive multiple sclerosis

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

A study to evaluate the effectiveness and safety of ritlecitinib tosilate and loratadine in adults with chronic spontaneous urticaria (hives)

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Loratadine
  • Sponsor:Pfizer Inc.

A Study Comparing Empasiprubart Versus Intravenous Immunoglobulin in Adults With Chronic Inflammatory Demyelinating Polyneuropathy

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Sponsor:Argenx
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.